News
Biopharmaceutical firms in the U.S. and Europe are turning to China’s biotech sector for new medicines, with licensing ...
The asset deal thrusts AbbVie to the forefront of the psychedelic field, handing it a therapy that recently scored positive ...
The agency said it had become aware of more reports of serious adverse events, leading center director Vinay Prasad to ...
An $885M deal with BeOne Medicine gives the pharma financier rights to a revenue stream from global sales of Imdelltra, which ...
Anne White, a 30-year company veteran who previously led the company’s oncology unit, will step down as head of Lilly ...
A refinancing deal will delay the maturity of $700 million in debt until 2030, allowing the company to “fully fund” its ...
Tough times in the industry are forcing changes in investment and governance that should result in a healthier sector, the ...
RFK Jr. has his sights set on increasing oversight and enforcement against drugmakers that run afoul of advertising laws.
Analysts found the agency's decision to cancel the meeting encouraging. Elsewhere, the Novo Holdings-owned CDMO cut about 350 staff in Maryland.
The FDA said data for PTC's drug did not prove "substantial evidence of efficacy." Elsewhere, the FDA delayed its decision on ...
The company plans to continue with a lower dose and a change in the pre-treatment regimen after a trial participant died ...
The two trading partners documented provisions of a deal that would set a 15% tariff on many EU imports, including cars, auto ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results